What medications decrease vascular permeability?

Drugs That Decrease Vascular Permeability

Catecholaminergic vasopressors (epinephrine and norepinephrine) are the most effective medications for reducing vascular permeability, working through β1- and β2-adrenergic receptor mechanisms to stabilize endothelial barriers. 1

Primary Agents: Catecholamines

The strongest evidence demonstrates that epinephrine and norepinephrine directly reduce endothelial permeability through multiple mechanisms 1:

• Mechanism of action: These agents induce actin cytoskeletal rearrangement and normalize membrane expression of adherens-junction proteins (VE-cadherin) and tight-junction proteins (zona occludens-1)
• Receptor pathway: Both β1- and β2-adrenergic receptors mediate the barrier-stabilizing effects, while α-adrenergic receptors do not contribute to permeability reduction
• Clinical context: These effects occur independently of their hemodynamic actions, meaning they stabilize vascular barriers even beyond their blood pressure effects

Important Caveat

While catecholamines reduce permeability, they do not decrease inflammatory cytokine production (IL-6, IL-8, MCP-1), indicating that permeability and inflammation are regulated through separate pathways 1.

Alternative Agents with Permeability-Reducing Effects

Corticosteroids

Dexamethasone reduces blood-tumor barrier permeability by decreasing ZO-1 gap formation 2:

• Effective in cerebral metastases and vasogenic edema
• Works through tight junction stabilization

Glyburide (Glibenclamide)

This sulfonylurea receptor 1 (SUR1) inhibitor demonstrates equal or superior efficacy to dexamethasone for reducing vascular permeability 2:

• Particularly effective in cerebral edema from metastases
• Decreases ZO-1 gap formation (P < 0.001)
• Safe, inexpensive alternative to steroids
• Effective in both small cell lung cancer and melanoma brain metastases

NSAIDs (Cyclooxygenase Inhibitors)

Most NSAIDs effectively block VEGF-induced vascular permeability 3:

• Selective COX-2 inhibitors show particular efficacy
• Acetaminophen does NOT reduce permeability
• Variable effects on angiogenesis depending on the cytokine involved (bFGF vs VEGF)

Prostacyclin (Low-Dose)

Extremely potent at low doses for reducing capillary permeability 4:

• Effective at doses as low as 0.1 ng/kg/min (8% reduction)
• Maximum effect at 2 ng/kg/min (30% reduction below baseline)
• Can counteract TNF-α and histamine-induced permeability increases
• Works without affecting vascular tone or capillary pressure at therapeutic doses

Anti-VEGF Agents

Bevacizumab reduces vascular permeability in tumor settings 5:

• Decreases K_trans (permeability coefficient)
• Note: This simultaneously reduces chemotherapy delivery in some tumor regions
• Clinical application limited to oncology settings

Agents That Do NOT Reduce Permeability

Vasopressin and angiotensin-II do not affect endothelial permeability despite their vasoconstrictive properties 1. This is a critical distinction when choosing vasopressors in shock states where barrier dysfunction is present.

Clinical Algorithm for Selection

In septic shock with barrier dysfunction:

1. First-line: Norepinephrine (dual benefit of hemodynamic support + permeability reduction) 1
2. Avoid: Vasopressin or angiotensin-II as primary agents if permeability is a concern

In cerebral edema from metastases:

1. First-line: Glyburide (equal efficacy to dexamethasone, fewer side effects) 2
2. Alternative: Dexamethasone if glyburide contraindicated

In inflammatory conditions with increased permeability:

1. Consider: Low-dose prostacyclin (2 ng/kg/min) 4
2. Adjunct: Selective COX-2 inhibitors 3

Key Pitfall to Avoid

Do not assume all vasopressors reduce permeability—only catecholamines (epinephrine/norepinephrine) have this property. Choosing vasopressin or angiotensin-II for hemodynamic support will not address endothelial barrier dysfunction 1.